Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.34 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.34 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.34 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.34 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.33 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | PTGES | O14684 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14911427 | 1.00 | CA1 (0.38) | CA1CA2CA7CA9PIM1 | |
| SCHEMBL23914619 | 0.82 | CA1 (0.39) | CA1CA2CA7CA9PIM1 | |
| SCHEMBL19807346 | 0.78 | MAOA (0.42) | CA1CA2CA7CA9SMN1; SMN2 | |
| SCHEMBL1398261 | 0.77 | ADORA2A (0.37) | PIM1CSNK1A1DYRK1ASMN1; SMN2ALDH1A1 | |
| SCHEMBL3890561 | 0.77 | SMARCA2 (0.36) | ALDH1A1MEN1KMT2A | |
| SCHEMBL3744088 | 0.77 | CA1 (0.42) | CA1CA2CA7CA9PDK2 | |
| SCHEMBL3902371 | 0.77 | MAP3K14 (0.40) | CA1CA2CA7CA9ALDH1A1 | |
| SCHEMBL2731181 | 0.77 | AKT1 (0.43) | CA1CA2CA7CA9PIM1 | |
| SCHEMBL21617656 | 0.77 | — | — | |
| SCHEMBL29582879 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025020886-A1 | AZAQUINAZOLINE RING DERIVATIVE AND USE THEREOF | 浙江星浩澎博医药有限公司 | 2025-01-30 | — | — | WO | disclosed |
| US-20240217968-A1 | PHARMACEUTICAL COMPOUND | Duke Street Bio Limited (GB) | 2024-07-04 | — | — | US | disclosed |
| CN-115785074-B | PARP7 inhibitors and uses thereof | 诺沃斯达药业(上海)有限公司 | 2024-05-07 | — | — | CN | disclosed |
| EP-4313300-A1 | PHARMACEUTICAL COMPOUND | Duke Street Bio Limited (GB) | 2024-02-07 | — | — | EP | disclosed |
| CN-117460723-A | Pharmaceutical compounds | 杜克街生物有限公司 | 2024-01-26 | — | — | CN | disclosed |
| US-11767312-B2 | Phthalazinone compound, and preparation method therefor and medical use thereof | GENENTECH, INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-11767312-B2 | Phthalazinone compound, and preparation method therefor and medical use thereof | GENENTECH, INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-20230242510-A1 | PHTHALAZINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | SHANGHAI JEMINCARE PHARMACEUTICALS CO LTD (CN) | 2023-08-03 | — | — | US | disclosed |
| US-20230242510-A1 | PHTHALAZINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | SHANGHAI JEMINCARE PHARMACEUTICALS CO LTD (CN) | 2023-08-03 | — | — | US | disclosed |
| US-20230131252-A1 | PHTHALAZINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | SHANGHAI JEYOU PHARMACEUTICAL CO., LTD. (CN) | 2023-04-27 | — | — | US | disclosed |
| EP-4166550-A1 | PHTHALAZINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | Shanghai Jemincare Pharmaceuticals Co., Ltd. (CN) | 2023-04-19 | — | — | EP | disclosed |
| CN-115785074-A | PARP7 inhibitors and uses thereof | 诺沃斯达药业(上海)有限公司 | 2023-03-14 | — | — | CN | disclosed |
| WO-2022207752-A1 | PHARMACEUTICAL COMPOUND | Duke Street Bio Limited (GB) | 2022-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240217968-A1 | PHARMACEUTICAL COMPOUND | F11, F12, ZYX | CA1 2185/4885CA2 1682/4885CA7 2086/4885 |
| US-11767312-B2 | Phthalazinone compound, and preparation method therefor and medical use thereof | CYP17A1, AR, NR5A1 | CA1 3919/4885CA2 2238/4885CA7 955/4885 |
| US-20230131252-A1 | PHTHALAZINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | CYP17A1, AR, NR5A1 | CA1 3919/4885CA2 2238/4885CA7 955/4885 |
| US-20230242510-A1 | PHTHALAZINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | CYP17A1, AR, NR5A1 | CA1 3919/4885CA2 2238/4885CA7 955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.